Aspiriant LLC Has $294,000 Stock Position in ResMed Inc. (NYSE:RMD)

Aspiriant LLC cut its holdings in shares of ResMed Inc. (NYSE:RMD) by 5.5% in the third quarter, HoldingsChannel reports. The fund owned 1,205 shares of the medical equipment provider’s stock after selling 70 shares during the quarter. Aspiriant LLC’s holdings in ResMed were worth $294,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of RMD. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of ResMed by 24.9% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,083 shares of the medical equipment provider’s stock worth $35,068,000 after purchasing an additional 35,273 shares during the period. Mediolanum International Funds Ltd purchased a new position in shares of ResMed during the 1st quarter valued at $2,246,000. Janney Montgomery Scott LLC increased its stake in shares of ResMed by 5.3% in the first quarter. Janney Montgomery Scott LLC now owns 81,313 shares of the medical equipment provider’s stock worth $16,102,000 after acquiring an additional 4,075 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of ResMed in the fourth quarter worth $7,535,000. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of ResMed by 8.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 171,632 shares of the medical equipment provider’s stock worth $37,586,000 after acquiring an additional 13,894 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other news, CFO Brett Sandercock sold 1,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $212.16, for a total transaction of $212,160.00. Following the transaction, the chief financial officer now owns 89,056 shares in the company, valued at approximately $18,894,120.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Brett Sandercock sold 1,000 shares of ResMed stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $212.16, for a total transaction of $212,160.00. Following the sale, the chief financial officer now directly owns 89,056 shares of the company’s stock, valued at $18,894,120.96. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Justin Leong sold 48,000 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $217.07, for a total value of $10,419,360.00. Following the completion of the transaction, the insider now directly owns 18,741 shares of the company’s stock, valued at approximately $4,068,108.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 123,874 shares of company stock valued at $28,151,142 in the last ninety days. Company insiders own 0.71% of the company’s stock.

ResMed Stock Up 0.2 %

RMD stock opened at $240.00 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.59 and a quick ratio of 1.69. The company has a 50-day moving average of $238.78 and a two-hundred day moving average of $215.88. The stock has a market capitalization of $35.22 billion, a price-to-earnings ratio of 34.63, a price-to-earnings-growth ratio of 2.17 and a beta of 0.69. ResMed Inc. has a 52-week low of $132.24 and a 52-week high of $255.18.

ResMed (NYSE:RMD) last released its earnings results on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.05. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter last year, the firm posted $1.60 EPS. The company’s revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts anticipate that ResMed Inc. will post 9.02 EPS for the current year.

ResMed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 19th. Investors of record on Thursday, August 15th were paid a dividend of $0.53 per share. This is a boost from ResMed’s previous quarterly dividend of $0.48. This represents a $2.12 annualized dividend and a yield of 0.88%. The ex-dividend date was Thursday, August 15th. ResMed’s dividend payout ratio is presently 30.59%.

Wall Street Analyst Weigh In

RMD has been the topic of a number of recent research reports. KeyCorp boosted their target price on ResMed from $238.00 to $251.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Bank of America increased their price objective on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, September 26th. Robert W. Baird initiated coverage on shares of ResMed in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $280.00 target price for the company. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Royal Bank of Canada lifted their price objective on shares of ResMed from $206.00 to $224.00 and gave the company a “sector perform” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and an average price target of $218.18.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.